Listen to Podcast of the Show
Richard and his wife Mari (who runs The Brighter Side, a boutique for women with cancer) interview Shaina Gross about a subject close to their hearts, breast cancer awareness and Susan G. Koman San Diego. Shaina Gross is President and CEO of Susan G. Komen San Diego and Shaina succeeds Laura Farmer Sherman, who retired after a decade in the role. She began her career in women’s health, providing education, access, and care to low-income, underserved women in North Carolina. She also worked closely with the immigrant community to break down barriers to health care. Prior to joining Komen San Diego, Shaina was the Senior Vice President at United Way, leading community collaborations and partnerships, programs, public policy and advocacy, and grant writing. Shaina believes that all people deserve the same opportunities to be healthy and receive quality care, and has dedicated her career toward this goal.
“Together, we will continue to achieve our mission of saving lives by meeting the most critical needs in San Diego County and investing in breakthrough research to prevent and cure breast cancer.”
Born and raised in New York, Shaina received her BA in Sociology and her Master’s Degree in Public Health, both from the University of North Carolina at Chapel Hill. She is a LEAD San Diego Graduate, a nominee for the Herb Klein Visionary Award, was recognized as a “40 under 40” business professional in San Diego, and was a 2014 winner of the San Diego Business Journal’s “Women Who Mean Business” award.
Outside of work, you can find her spending time with her family, seeking out live music, watching Tar Heel basketball, and enjoying the many great restaurants San Diego has to offer.
On Sunday, November, 5th 2017 Susan G. Koman San Diego will be holding their “Race for the Cure®” 5k and 1 Mile Walk/Run races in Balboa Park. 75% of the proceeds raised through “Race for the Cure®” stays in the community to help fund programs like screening diagnosis and treatment, safe and accurate breast cancer information, and patient navigation programs. 25% of the net proceeds goes toward Komen’s national priorities of new early detection technologies, understanding metastasis, and more effective treatments.